Two large phase 3 trials have been performed in patients with chronic constipation, and the clotide-treated groups had significantly higher rates of 3 or more complete spontaneous bowel movements per week and in increase in 1 or more complete spontaneous bowel movements from baseline during at least 9 of 12 weeks compared with placebo.